Print Page  Close Window
10-Q
PARATEK PHARMACEUTICALS, INC. filed this Form 10-Q on 05/09/2018
Entire Document
 

 

Paratek Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

Three Months Ended

March 31,

 

 

 

2018

 

 

2017

 

License and royalty revenue

 

$

10

 

 

$

18

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

14,864

 

 

 

18,657

 

General and administrative

 

 

11,873

 

 

 

8,363

 

Changes in fair value of contingent consideration

 

 

(15

)

 

 

(231

)

Total operating expenses

 

 

26,722

 

 

 

26,789

 

Loss from operations

 

 

(26,712

)

 

 

(26,771

)

Other income and expenses:

 

 

 

 

 

 

 

 

Interest expense

 

 

(1,507

)

 

 

(1,132

)

Interest income

 

 

475

 

 

 

240

 

Other loss, net

 

 

(6

)

 

 

(7

)

Net loss

 

$

(27,750

)

 

$

(27,670

)

Other comprehensive income:

 

 

 

 

 

 

 

 

Unrealized loss on available-for-sale securities, net of tax

 

 

(21

)

 

 

(38

)

Comprehensive loss

 

$

(27,771

)

 

$

(27,708

)

Net loss per share - basic and diluted

 

$

(0.91

)

 

$

(1.14

)

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

Basic and diluted

 

 

30,566,694

 

 

 

24,196,158

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

 

3